Feng Yang

Dr. Feng Yang

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Science of The Total Environment
Verified
Journal Article
Closed access
Wenhui QiuWenhui Qiu
Wenhui Qiu
XLXinjie Liu
Xinjie Liu
FYFeng Yang
Feng Yang
RLRongzhen Li
Rongzhen Li
YXYing Xiong
Ying Xiong
CZChunmiao Zheng
Chunmiao Zheng

1 December 2018 in Chemosphere
Verified
Journal Article
Closed access
FYFeng Yang
Feng Yang
Wenhui QiuWenhui Qiu
Wenhui Qiu
RLRongzhen Li
Rongzhen Li
JHJiaqi Hu
Jiaqi Hu
SLShusheng Luo
Shusheng Luo
CZChunmiao Zheng
Chunmiao Zheng

1 June 2019 in Ecotoxicology and Environmental Safety
Verified
Journal Article
Closed access
Wenhui QiuWenhui Qiu
Wenhui Qiu
SLShuai Liu
Shuai Liu
FYFeng Yang
Feng Yang
PDPeiyao Dong
Peiyao Dong
MYMing Yang
Ming Yang
CZChunmiao Zheng
Chunmiao Zheng

1 May 2013 in Theriogenology
Verified
Journal Article
Closed access
WDWen-Bo Deng
Wen-Bo Deng
ZTZhen Tian
Zhen Tian
XLXiao-Huan Liang
Xiao-Huan Liang
BWBao-Chen Wang
Bao-Chen Wang
FYFeng Yang
Feng Yang
ZYZeng-Ming Yang
Zeng-Ming Yang

23 December 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
YXYan-Ming Xu
Yan-Ming Xu
DWDan-Dan Wu
Dan-Dan Wu
WZWei Zheng
Wei Zheng
FYFei-Yuan Yu
Fei-Yuan Yu
FYFeng Yang
Feng Yang
Andy T. Y. LauAndy T. Y. Lau
Andy T. Y. Lau
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Yan-Ming Xu1, Dan-Dan Wu1, *, Wei Zheng1, *, Fei-Yuan Yu1, Feng Yang1, Yue Yao1, Yuan Zhou2, Yick-Pang Ching2, Andy T. Y. Lau1 1Laboratory of Cancer Biology and Epigenetics, Department of Cell Biology and Genetics, Shantou University Medical College, Shantou, Guangdong 515041, P. R. China 2School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, P. R. China *These authors contributed equally to this work Correspondence to: Andy T. Y. Lau, e-mail: andytylau@stu.edu.cn Keywords: cadmium, human lung cells, antibody array, post-translational modifications, mitochondrial pathway Received: May 19, 2015 Accepted: December 08, 2015 Published: December 23, 2015 ABSTRACT Protein array technology is a powerful platform for the simultaneous determination of the expression levels of a number of proteins as well as post-translational modifications such as phosphorylation. Here, we screen and report for the first time, the dominant signaling cascades and apoptotic mediators during the course of cadmium (Cd)-induced cytotoxicity in human bronchial epithelial cells (BEAS-2B) by antibody array analyses. Proteins from control and Cd-treated cells were captured on Proteome Profiler™ Arrays for the parallel determination of the relative levels of protein phosphorylation and proteins associated with apoptosis. Our results indicated that the p38 MAPK- and JNK-related signal transduction pathways were dramatically activated by Cd treatment. Cd potently stimulates the phosphorylations of p38α (MAPK14), JNK1/2 (MAPK8/9), and JUN; while the phosphorylations of Akt1, ERK1/2 (MAPK3/1), GSK3β, and mTOR were suppressed. Moreover, there was an induction of proapoptotic protein BAX, release of cytochrome c (CYCS) from mitochondria, activation of caspase-3/9 (CASP3/9); as well as decreased expression of cell cycle checkpoint proteins (TP53, p21, and p27) and several inhibitors of apoptosis proteins (IAPs) [including cIAP-1/2 (BIRC2/3), XIAP (BIRC4), and survivin (BIRC5)]. Pretreatment of cells with the thiol antioxidant glutathione or p38 MAPK/JNK inhibitors before Cd treatment effectively abrogated ROS activation of p38 MAPK/JNK pathways and apoptosis-related proteins. Taken together, our results demonstrate that Cd causes oxidative stress-induced apoptosis; and the p38 MAPK/JNK and mitochondrial pathways are more importantly participated for signal transduction and the induction of apoptosis in Cd-exposed human lung cells.

21 May 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MZMeng Zhang
Meng Zhang
FYFeng Yang
Feng Yang
JWJia Wang
Jia Wang
ZJZhao Jianwei
Zhao Jianwei
TLTing Li
Ting Li
MWMing-Wei Wang
Ming-Wei Wang
G protein-coupled receptor 119 (GPR119) is highly expressed in pancreatic β cells and enteroendocrine cells. It is involved in glucose-stimulated insulin secretion and glucagon-like peptide-1 (GLP-1) release, thereby representing a promising target for the treatment of type 2 diabetes. Although a number of GPR119 agonists were developed, no positive allosteric modulator (PAM) to this receptor has been reported. Here we describe a high-throughput assay for screening GPR119 PAMs and agonists simultaneously. Following screening of a small molecule compound library containing 312,000 synthetic and natural product-derived samples, one potent GPR119 agonist with novel chemical structure, MW1219, was identified. Exposure of MIN6 and GLUTag cells to MW1219 enhanced glucose-stimulated insulin secretion and GLP-1 release; once-daily oral dosing of MW1219 for 6 weeks in diabetic db/db mice reduced hemoglobin A1c (HbA1c) and improved plasma glucose, insulin and GLP-1 levels; it also increased glucose tolerance. The results demonstrate that MW1219 is capable of effectively controlling blood glucose level and may have the potential to be developed as a new class of anti-diabetic agents.